Literature DB >> 18240340

The blind men 'see' the elephant-the many faces of fatty liver disease.

Madhusudana Girija Sanal1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a group of diseases with excess fat in liver in the absence of a poorly defined limit of alcohol consumption. Most common variety, a universal public health problem, is associated with insulin resistance caused by a host of genetic and epigenetic defects modulated by life style and environmental factors. In fact the term NAFLD is loose to incorporate so many etiologies except alcoholism and few other etiologies, presenting as fat in liver. However as a sign fatty liver is very important in predicting the risk of diabetes, cardiovascular disease, stroke, cirrhosis and cancer. Abnormal fat accumulation can result from several defects in nuclear receptors associated with lipid sensing, synthesis and oxidation like LXR, FXR, SREBP, ChREBP and PPAR; defects in the lipid influx-efflux channels, insulin signaling, proteins involved in fatty acid catabolism, defects in adipose tissue development and function, inappropriate nutrition and finally defects in neural regulatory mechanisms. The progress of the disease is determined by the basic defects which results in fat accumulation, an individual's immunological response to the accumulated fat and its derivatives and the oxidant stress response. Congregation of unrelated genetic defects under same diagnosis 'NAFLD' can result in inefficient patient management. Further studies are required to understand the molecular basis of fatty liver to enable a personalized management of diseases presenting as fatty liver in the absence of alcohol abuse.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18240340      PMCID: PMC2687050          DOI: 10.3748/wjg.14.831

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  134 in total

Review 1.  Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis.

Authors:  C N Hales; D J Barker
Journal:  Diabetologia       Date:  1992-07       Impact factor: 10.122

2.  Sudden infant death and long-chain 3-hydroxyacyl-CoA dehydrogenase.

Authors:  R J Wanders; M Duran; L Ijlst; J P de Jager; A H van Gennip; C Jakobs; L Dorland; F J van Sprang
Journal:  Lancet       Date:  1989-07-01       Impact factor: 79.321

Review 3.  Thioredoxin.

Authors:  A Holmgren
Journal:  Annu Rev Biochem       Date:  1985       Impact factor: 23.643

Review 4.  Nonalcoholic fatty liver disease and the metabolic syndrome.

Authors:  G Marchesini; M Babini
Journal:  Minerva Cardioangiol       Date:  2006-04       Impact factor: 1.347

Review 5.  Insulin resistance and atherosclerosis.

Authors:  Clay F Semenkovich
Journal:  J Clin Invest       Date:  2006-07       Impact factor: 14.808

6.  Nutritional influences on lipogenesis and thermogenesis after a carbohydrate meal.

Authors:  K J Acheson; Y Schutz; T Bessard; E Ravussin; E Jéquier; J P Flatt
Journal:  Am J Physiol       Date:  1984-01

Review 7.  Microvesicular steatosis of the liver.

Authors:  M L Hautekeete; C Degott; J P Benhamou
Journal:  Acta Clin Belg       Date:  1990       Impact factor: 1.264

Review 8.  [Role of liver biopsy in the diagnosis of NASH].

Authors:  Kazuyuki Kanemasa; Yoshio Sumida
Journal:  Nihon Rinsho       Date:  2006-06

9.  Fatty liver, carotid disease and gallstones: a study of age-related associations.

Authors:  Amedeo Lonardo; Silvia Lombardini; Federica Scaglioni; Stefano Ballestri; Anna-Maria Verrone; Marco Bertolotti; Lucia Carulli; Dorval Ganazzi; Nicola Carulli; Paola Loria
Journal:  World J Gastroenterol       Date:  2006-09-28       Impact factor: 5.742

10.  Q-fever. The liver and bone marrow pathology.

Authors:  J R Srigley; H Vellend; N Palmer; M J Phillips; W R Geddie; A W Van Nostrand; V D Edwards
Journal:  Am J Surg Pathol       Date:  1985-10       Impact factor: 6.394

View more
  21 in total

1.  Decreased liver triglyceride content in adult rats exposed to protein restriction during gestation and lactation: role of hepatic triglyceride utilization.

Authors:  Rani J Qasem; Jing Li; Hee Man Tang; Veron Browne; Claudia Mendez-Garcia; Elizabeth Yablonski; Laura Pontiggia; Anil P D'Mello
Journal:  Clin Exp Pharmacol Physiol       Date:  2015-04       Impact factor: 2.557

Review 2.  Angiogenesis and liver fibrosis.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Hepatol       Date:  2015-03-27

3.  Angiogenesis: a phenomenon which aggravates chronic liver disease progression.

Authors:  Michał Kukla
Journal:  Hepatol Int       Date:  2012-07-26       Impact factor: 6.047

4.  Proteasome inhibitor treatment reduced fatty acid, triacylglycerol and cholesterol synthesis.

Authors:  Joan Oliva; Samuel W French; Jun Li; Fawzia Bardag-Gorce
Journal:  Exp Mol Pathol       Date:  2012-03-16       Impact factor: 3.362

Review 5.  Dissociating fatty liver and diabetes.

Authors:  Zheng Sun; Mitchell A Lazar
Journal:  Trends Endocrinol Metab       Date:  2012-10-05       Impact factor: 12.015

Review 6.  Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal.

Authors:  Valerio Nobili; Arun J Sanyal
Journal:  J Gastroenterol       Date:  2011-10-08       Impact factor: 7.527

7.  Chemopreventive effects of RXR-selective rexinoid bexarotene on intestinal neoplasia of Apc(Min/+) mice.

Authors:  Naveena B Janakiram; Altaf Mohammed; Li Qian; Chang-In Choi; Vernon E Steele; Chinthalapally V Rao
Journal:  Neoplasia       Date:  2012-02       Impact factor: 5.715

8.  Glp-1 analog, liraglutide, ameliorates hepatic steatosis and cardiac hypertrophy in C57BL/6J mice fed a Western diet.

Authors:  Jamie E Mells; Ping P Fu; Shvetank Sharma; Darin Olson; Lihong Cheng; Jeffrey A Handy; Neeraj K Saxena; Dan Sorescu; Frank A Anania
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-10-28       Impact factor: 4.052

9.  Induction of liver steatosis and lipid droplet formation in ATF6alpha-knockout mice burdened with pharmacological endoplasmic reticulum stress.

Authors:  Keisuke Yamamoto; Kazuna Takahara; Seiichi Oyadomari; Tetsuya Okada; Takashi Sato; Akihiro Harada; Kazutoshi Mori
Journal:  Mol Biol Cell       Date:  2010-07-14       Impact factor: 4.138

10.  Anti-obesity effect of Lactobacillus gasseri SBT2055 accompanied by inhibition of pro-inflammatory gene expression in the visceral adipose tissue in diet-induced obese mice.

Authors:  Masaya Miyoshi; Akihiro Ogawa; Satoshi Higurashi; Yukio Kadooka
Journal:  Eur J Nutr       Date:  2013-08-06       Impact factor: 5.614

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.